Ayr Wellness Announces Initial Closing of Restructuring, $275M Exit Facility, Amidst Liquidation Proceedings
summarizeSummary
Ayr Wellness Inc. announced the initial closing of its restructuring transactions, including a $275 million exit facility and transfer of Virginia operations to a new entity, as the company continues its liquidation and wind-down proceedings.
check_boxKey Events
-
Restructuring Progresses
The company announced the initial closing of the transfer of its Virginia operations into Arboretum Virginia LLC, a new entity established by senior secured noteholders as part of previously announced restructuring transactions.
-
New Exit Facility Secured
A $275 million senior secured delayed draw term loan facility (Exit Facility) has been closed and initially funded for Arboretum, bearing interest at 13.00% per annum and maturing in five years.
-
Debt Converted to Equity in New Entity
A pro rata portion of the existing Bridge Facility debt and senior secured notes are being rolled over or exchanged for new equity interests in Arboretum Investments LLC, the ultimate parent entity of Arboretum.
-
Company Liquidation Continues
Ayr Wellness Inc. is continuing its proceedings under the Companies' Creditors Arrangement Act (Canada) to effectuate a liquidation and wind-down of the original company.
auto_awesomeAnalysis
This filing confirms the initial execution of Ayr Wellness's previously announced restructuring, which involves transferring assets to a new entity (Arboretum) backed by senior secured noteholders and securing a substantial $275 million exit facility for that new entity. Critically, this occurs concurrently with the original company's ongoing liquidation and wind-down proceedings under Canadian law. For existing shareholders of Ayr Wellness Inc., this development signals the progression towards the likely elimination of their equity value as the company liquidates. The exit facility and asset transfers are part of the process to salvage operations under new ownership, effectively leaving current shareholders with little to no recovery.
At the time of this filing, AYRWF was trading at $0.01 on OTC in the Life Sciences sector, with a market capitalization of approximately $13.1M. The 52-week trading range was $0.00 to $0.33. This filing was assessed with negative market sentiment and an importance score of 10 out of 10.